Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.
Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).
EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.
The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.
The Stephenson Global Pancreatic Cancer Research Institute and its partner, City of Hope, announced the six inaugural recipients of the Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection, and treatment of pancreatic cancer (The Cancer Letter, Sept. 17, 2024).
Dispatch Bio, a company aiming to engineer a universal immunotherapy treatment across solid tumors, announced its official launch.
Geraldine O’Sullivan Coyne was appointed system head of Northwell and principal investigator for the START Center for Cancer Research, a newly established unit at the health system aimed at bringing innovative early stage clinical trials to patients in a community-based cancer center.
NIH has announced it will stop issuing funding opportunities solely dedicated to animal models, but has not published any formal guidance related to the announcement, and researchers are unclear on when or whether further policy materials are to be expected.
Monica L. Baskin joined VCU Massey Comprehensive Cancer Center as deputy director of research.
